Clinical Trial Update: Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing dosing interval and optimal dose of AYP-101 for reducing submental fullness in the chin area has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Severe Submental Fullness
• Submental Fullness

Drugs mentioned

• AYP-101

Snippet

Sponsor: AMIpharm Co., Ltd. | Conditions: Moderate or Severe Submental Fullness | Phase 2 | Status: COMPLETED